The "Deemed To Be a License" Provision of the BPCI Act; Questions and Answers; Guidance for Industry
NonrulemakingOtherFDA-2015-D-4750-0439
Comments
4,223
Awaiting comments
Deadline
No comment period
Net support
-100%
Support minus oppose · campaigns included
-98% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Mar 5, 2020
- Comment period
- Mar 5, 2020 – ?
- Agency
- Food and Drug Administration (FDA)
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 520 of 4,223 comments
12%· analysis in progress
Stance breakdown
-98%
Net support
Support5Oppose515
Showing organic comments only. With campaigns included, net support is -100%.
Who commented
Breakdown by commenter type, organic comments only.
Business
1
Individual
519
Comments over time
Weekly arrivals, stacked by stance, organic only.
Posted Mar 5, 2020
Support5Oppose515Other0
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Form letters
Campaigns
Organized form-letter drives, separated from organic one-off comments.
80%of comments arrived through 3 form-letter campaigns — 3,391 of 4,223 comments. 832 are organic.
Campaign3,391Organic832Not yet determined0
⚑
Preserve Access to Desiccated Thyroid Extract
Sponsor unknown
2,22052.6% of total
Oppose
⚑
Oppose FDA Reclassification of DTE
Sponsor unknown
82419.5% of total
Oppose
⚑
Oppose DTE Biologic Reclassification
Sponsor unknown
3478.2% of total
Oppose
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 4,223 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.